MILWAUKEE, Sept. 30, 2019 /PRNewswire/ -- Ademi &
O'Reilly, LLP is investigating Dova Pharmaceuticals, Inc. (Nasdaq:
DOVA) for possible breaches of fiduciary duty and other
violations of the law in connection with the sale of Dova to
Swedish Orphan Biovitrum.
Click here to learn how to join the action:
http://ademilaw.com/case/dova-pharmaceuticals-inc or call
Guri Ademi toll-free at
866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Dova's financial outlook is
improving and yet shareholders will receive only receive
$27.50 per share in cash, along with
one non-tradeable Contingent Value Right that entitles them to an
additional $1.50 per share in cash
upon regulatory approval of DOPTELET for the treatment of
chemotherapy-induced thrombocytopenia, representing a total
potential consideration of $29.00 per
share, or a total potential consideration of up to $915 million on a fully diluted basis..
Swedish Orphan Biovitrum is acquiring Dova at a substantial
discount. The merger agreement unreasonably limits competing
bids for Dova by prohibiting solicitation of further bids, and
imposing a termination penalty if Dova accepts a superior
bid. Dova insiders will receive millions of dollars as part
of change of control arrangements. We are investigating on
the conduct of Dova's board of directors, and whether they are (i)
fulfilling their fiduciary duties to all shareholders, and (ii)
obtaining a fair and reasonable price for Dova.
If you own common stock in Dova and wish to obtain additional
information, please contact Guri
Ademi either at gademi@ademilaw.com or toll-free:
866-264-3995, or http://ademilaw.com/case/dova-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts,
mergers, and individual shareholder rights throughout the
country. For more information, please feel free to call us.
Attorney advertising. Prior results do not guarantee
similar outcomes.
Contacts
Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-dova-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-sale-to-swedish-orphan-biovitrum-ab-300927618.html
SOURCE Ademi & O'Reilly, LLP
